Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Megan Ward

Nurse Practitioner Louisville, KY Nurse Practitioner

NPI 1114909819 CMS profile 11071192

1169 Eastern Pkwy Ste 1234, Louisville, KY 40217

Open in the dashboard

General payments

$234

6 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Megan Ward of Louisville, KY is reported in the CMS Open Payments database as having received $234 across 6 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 42nd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $216 5
2021 General $18 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Megan Ward
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Megan Ward were reported at $216. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Megan Ward Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $18 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $0 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $216 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $123 1 payment
  2. Bayer HealthCare Pharmaceuticals Inc. $44 2 payments
  3. AstraZeneca Pharmaceuticals LP $28 1 payment
  4. Janssen Biotech, Inc. $22 1 payment
  5. Jazz Pharmaceuticals Inc. $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $234 6 payments
Products named General payments · program years 2021–2025
  1. REPATHA $123 1 payment
  2. Nubeqa $44 2 payments
  3. Xofigo $44 2 payments
  4. DARZALEX $22 1 payment
  5. TALVEY $22 1 payment
  6. TECVAYLI $22 1 payment
  7. ZEPZELCA $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

815

Median for Nurse Practitioner: 389

Drug cost

$68,141

Median for Nurse Practitioner: $21,885

Branded share of claims

19.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 37 $34,319
Eliquis Apixaban Brand 17 $27,322
Albuterol Sulfate Hfa Albuterol Sulfate Brand 27 $761
Metoprolol Succinate Generic 57 $697
Levothyroxine Sodium Generic 67 $697
Atorvastatin Calcium Generic 94 $627
Synthroid Levothyroxine Sodium Brand 13 $583
Losartan Potassium Generic 33 $397
Simvastatin Generic 64 $355
Rosuvastatin Calcium Generic 40 $270

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$20,483

Of which drugs: $5,768

Medicare patients

109

Average age 71

Services billed

364

62 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 46%
Arthritis 33%
Ischemic heart disease 20%
Osteoporosis 18%
Diabetes 17%
Atrial fibrillation 12%
Cancer 11%
Depression 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscv2 vac 30mcg trs-suc im 91320 Office 21 26 $3,479
Vaccine for influenza for injection into muscle 90662 Office 13 13 $1,064

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

6 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record